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Abstract
Background: Methotrexate is one of the earliest cytotoxic drugs used in cancer therapy, and despite the
isolation of multiple other folate antagonists, methotrexate maintains its significant role as a treatment for
different types of cancer and other disorders. The usefulness of treatment with methotrexate is limited by
the development of drug resistance, which may be acquired through different ways. To get insights into
the mechanisms associated with drug resistance and sensitization we performed a functional analysis of
genes deregulated in methotrexate resistant cells, either due to its co-amplification with the dhfr gene or
as a result of a transcriptome screening using microarrays.
Methods: Gene expression levels were compared between triplicate samples from either HT29 sensitive
cells and resistant to 10-5 M MTX by hybridization to the GeneChip® HG U133 PLUS 2.0 from Affymetrix.
After normalization, a list of 3-fold differentially expressed genes with a p-value < 0.05 including multiple
testing correction (Benjamini and Hochberg false discovery rate) was generated. RT-Real-time PCR was
used to validate the expression levels of selected genes and copy-number was determined by qPCR.
Functional validations were performed either by siRNAs or by transfection of an expression plasmid.
Results: Genes adjacent to the dhfr locus and included in the 5q14 amplicon were overexpressed in HT29
MTX-resistant cells. Treatment with siRNAs against those genes caused a slight reduction in cell viability
in both HT29 sensitive and resistant cells. On the other hand, microarray analysis of HT29 and HT29 MTX
resistant cells unveiled overexpression of caveolin 1, enolase 2 and PKCα genes in resistant cells without
concomitant copy number gain. siRNAs against these three genes effectively reduced cell viability and
caused a decreased MTX resistance capacity. Moreover, overexpression of E-cadherin, which was found
underexpressed in MTX-resistant cells, also sensitized the cells toward the chemotherapeutic agent.
Combined treatments targeting siRNA inhibition of caveolin 1 and overexpression of E-cadherin markedly
reduced cell viability in both sensitive and MTX-resistant HT29 cells.
Conclusion: We provide functional evidences indicating that caveolin 1 and E-cadherin, deregulated in
MTX resistant cells, may play a critical role in cell survival and may constitute potential targets for
coadjuvant therapy.
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Background
Colorectal cancer is the third most common form of can-
cer and the second leading cause of cancer-related death in
the Western world. Colon cancer causes 655,000 deaths
worldwide per year [1]. Therapy is usually through sur-
gery, followed in many cases by chemotherapy, which is
used to slow tumor growth, to shrink tumor size and to
reduce the likelihood of metastasis development.
Chemotherapy effectiveness in cancer cells is compro-
mised by the achievement of drug resistance. Therefore,
gaining insight into the mechanisms underlying drug
resistance is basic to develop more effective therapeutic
approaches. Morales et al. [2] hypothesized that the
genetic features related with the progression pathway in
colorectal cancer may condition its chemoresistance capa-
bility. In fact, it has been described that the tumor's ability
to survive, grow and metastasize is conditioned by its
genetic and phenotypic heterogeneity [3].
Methotrexate (MTX) is an antimetabolite and antifolate
drug used in treatment of cancer and autoimmune dis-
eases. MTX competitively and reversibly inhibits dihydro-
folate reductase (DHFR), an enzyme that participates in
folate metabolism, and essential for DNA synthesis and
cell growth [4]. MTX is used for the treatment of lymphob-
lastic leukemia, lymphoma, osteosarcoma, breast cancer,
and head and neck cancer [5]. Treatments combining
MTX and other drugs are used in colorectal cancer [6-8].
However, MTX resistance can be easily acquired through
different ways, although amplification of the target gene
(dhfr) has been shown to be the most important mecha-
nism of resistance in cultured cells [9-11]. Indeed, ampli-
fication of 5q12-14 regions, where dhfr  is located, has
been described in MTX-resistant HT29 cells [2].
In the present study, we wanted to identify genes impli-
cated in MTX resistance in HT29 colon cancer cells and to
explore their relative contribution to this phenotype. We
analyzed the differential gene expression between MTX-
resistant and MTX-sensitive HT29 cells using oligonucle-
otide microarrays containing the full human genome.
Changes in the DNA content between both cell lines were
also determined. We showed a role for specific differen-
tially expressed genes in MTX resistance. Using siRNAs
against caveolin 1, enolase 2 and PKCα or plasmid over-
expression for E-cadherin, a clear chemosensitization
toward MTX was observed.
Methods
Cell Culture
Human colon adenocarcinoma cell line HT29 was rou-
tinely grown in Ham's F12 medium supplemented with
7% fetal bovine serum (FBS, both from Gibco) at 37°C in
a 5% CO2 humidified atmosphere. Cells resistant to 10-5
M MTX, which corresponds to a 1000-fold increase in
resistance with respect to the sensitive cells, were previ-
ously obtained in the laboratory [12] upon incubation
with stepwise concentrations of MTX (Lederle) and were
rutinely grown in selective DHFR medium (-GHT
medium, GIBCO) lacking glycine, hypoxanthine and thy-
midine, the final products of DHFR activity. This medium
was supplemented with 7% dialyzed fetal bovine serum
(GIBCO).
Microarrays
Gene expression was analyzed by hybridization to the
GeneChip®  Human Genome U133 PLUS 2.0 from
Affymetrix, containing over 47,000 transcripts and vari-
ants. Total RNA for oligo arrays was prepared from tripli-
cate samples of both HT29 sensitive and resistant cells
using the RNAeasy Mini kit (Qiagen) following the rec-
ommendations of the manufacturer. Labeling, hybridiza-
tion and detection were carried out following the
manufacturer's specifications. The data discussed in this
publication have been deposited in NCBIs Gene Expres-
sion Omnibus [13] and are accessible through GEO Series
accession number GSE11440.
Microarray data analysis
Quantification was carried out with GeneSpring GX soft-
ware v 7.3.1 (Silicon Genetics), which allows multi-filter
comparisons using data from different experiments to per-
form the normalization, generation of restriction lists and
functional classifications of the differentially expressed
genes. Normalization was applied in two steps: i) "per
Chip normalization" by which each measurement was
divided by the 50th percentile of all measurements in its
array; and ii) "per Gene normalization" by which all the
samples were normalized against the median of the con-
trol samples (HT29 sensitive cells). The expression of each
gene was reported as the ratio of the value obtained after
each condition relative to the control condition after nor-
malization of the data. Then, data were filtered using the
control strength, a control value calculated using the
Cross-Gene Error Model on replicates [14] and based on
average base/proportional value. Measurements with
higher control strength are relatively more precise than
measurements with lower control strength. Genes that did
not reach this value were discarded. Additional filtering
was performed to determine differentially expressed
genes. A restriction t-test p-value of less than 0.05 includ-
ing multiple testing correction (Benjamini and Hochberg
false discovery rate) was applied. The output of this anal-
ysis was then filtered by fold expression, to specifically
select those genes that had a differential expression of at
least 3-fold. The 375 transcripts included in this list can be
viewed in Additional file 1.BMC Medical Genomics 2008, 1:35 http://www.biomedcentral.com/1755-8794/1/35
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RT-Real-Time PCR
mRNA levels of the different selected genes were deter-
mined by RT-Real-time PCR. Total RNA was extracted
from cells (4 × 106) using Ultraspec™ RNA reagent (Bio-
tecx) following the recommendations of the manufac-
turer. Complementary DNA was synthesized in a total
volume of 20 μl from RNA samples by mixing 500 ng of
total RNA, 125 ng of random hexamers (Roche), in the
presence of 75 mM KCl, 3 mM MgCl2, 10 mM dithiothre-
itol, 20 units of RNasin (Promega), 0.5 mM dNTPs
(AppliChem), 200 units of M-MLV reverse transcriptase
(Invitrogen) and 50 mM Tris-HCl buffer, pH 8.3. The reac-
tion mixture was incubated at 37°C for 60 min and the
cDNA product was used for subsequent Real-time PCR
amplification using SYBR Green. A standard 20 μl reaction
contained 25 ng of the cDNA mixture, 0.5 μM of the for-
ward and reverse primers and the SYBR Green Master Mix.
Primers used are listed in the Additional file 2.
Determination of gene copy number
Genomic DNA from either HT29 sensitive or resistant
cells was obtained with the Wizard™ Genomic DNA Puri-
fication Kit (Promega) following the manufacturer's rec-
ommendations. Five nanograms of DNA were used for
Real-Time PCR amplification in a 20 μl reaction contain-
ing 0.5 μM of the forward and reverse primers and the
SYBR Green Master Mix in an ABI Prism 7000 Sequence
Detection System (Applied Biosystems). A list of the prim-
ers used is provided as Additional file 3.
Functional validations
A) transfection of siRNAs against selected genes
HT29 cells (30,000) were plated in 1 ml of -GHT medium
and transfection was performed eighteen hours later. For
each well, 4 μl of Lipofectamine™ 2000 (Invitrogen) in
100 μl of serum free -GHT medium were mixed in Eppen-
dorf tubes with 100 nM of siRNA in 100 μl of serum free
-GHT medium. The mixture was incubated at room tem-
perature for 20 min before addition to the cells. MTX (5 ×
10-8 M) was added 48 hours after siRNA treatment and
MTT assays were performed [15] after 5 days from the
beginning of the treatment. Treatment of HT29 resistant
cells was performed following the same protocol using 2
μl of Lipofectamine™ 2000 and 10-5 M MTX. When screen-
ing for mRNA levels of the different genes after siRNA
treatment, 30,000 cells, either sensitive or resistant, were
incubated with increasing amounts of siRNA (1–100 nM)
maintaining a 3:1 ratio (μl of Lipofectamine : μg siRNA)
and following the procedure previously described. Cells
were harvested 48 hours after siRNA treatment for RNA
extraction and RT-Real-time PCR. In the combination
experiments with siRNAs, 100 nM of each siRNA were
diluted in the same eppendorf containing 100 μl of serum
free -GHT medium and combined with Lipofectamine™
2000 as described above. MTX was added as in the single
siRNA experiments, mRNA levels were determined and
MTT was performed as previously described. In all cases, a
non-related siRNA was used as negative control. The treat-
ment was performed as described above and cell viability
and mRNA levels for each gene were quantified in paral-
lel. The siRNAs were designed using the software iRNAi.
Then, BLAST resources in NCBI were used to assess the
degree of specificity of the sequence recognition for these
siRNAs. We only selected the siRNAs that reported the tar-
get gene as the only mRNA hit. The sequences for the
sense strand of all siRNAs used are available in the supple-
mentary material provided (see Additional file 4).
B) transfection of an expression plasmid encoding for E-cadherin
HT29 cells were seeded into 6-well plates at a density of 3
× 104 cells/well in 1 ml of HAM F12 selective medium.
Eighteen hours later, transfections with the expression
plasmid for E-cadherin (pBATEM2-CDH) were performed
in the presence or in the absence of MTX. The overexpres-
sion of E-cadherin was monitored by determining its
mRNA levels after 48 h upon transfection. For each well,
Lipofectamine™ 2000 was diluted in 100 μl of serum free
-GHT medium and was combined with different amounts
of the plasmid (500 ng-5 μg) in 100 μl of serum free -GHT
medium, always maintaining a 2:1 ratio (μl of Lipo-
fectamine : μg of plasmid). After 20 min at room temper-
ature, the mixture was added to the cells. When
combining pBATEM2-CDH transfection and MTX treat-
ment, 5 × 10-8 M MTX was added 48 h after transfection.
Cell viability was measured by the MTT assay after 5 days
from the beginning of the treatment. Treatment of HT29
resistant cells was performed following the same steps but
using 10-5 M MTX.
C) co-transfection of siCAV1 and pBATEM2-CDH
When transfection of siCAV1 and pBATEM2-CDH was
performed simultaneously, 100 nM of siRNA and 1 μg of
plasmid were diluted together in Eppendorf tubes with
100 μl of serum free -GHT medium and mixed with lipo-
fectamine™ 2000 in 100 μl of serum free -GHT medium (6
μl for the sensitive cells and 3 μl for the MTX-resistant
cells). The mixture was incubated at room temperature for
20 min before addition to the cells (3 × 104 cells/well in 1
ml of HAM F12 selective medium, pre-seeded eighteen
hours earlier). The mRNA levels after transfection were
determined for both genes as previously described and
MTT assay was used to determine cell viability.
Results
Identification of genes deregulated in association with 
MTX resistance
The expression profile of the 47,000 transcripts and vari-
ants included in the HG U133 PLUS 2.0 microarray from
Affymetrix was compared between HT29 sensitive cells
and resistant to 10-5 M MTX. GeneSpring GX softwareBMC Medical Genomics 2008, 1:35 http://www.biomedcentral.com/1755-8794/1/35
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v7.3.1 was used to analyze the results. A list of 3-fold dif-
ferentially expressed genes was generated as described in
Methods (Additional file 1). The expression values for
genes in this list can be viewed in their corresponding
chromosomal position (Figure 1). This overlapping view
evidenced a highly overexpressed region in chromosome
5 that covers dhfr  and the surrounding loci. The set of
upregulated genes in this location included dhfr, zfyve16,
msh3,  rasgrf2,  ssbp2,  xrcc4,  hapln1  and edil3  (Figure 2),
which were selected for further studies. Additional genes
that were clearly overexpressed or underexpressed and
located in other human chromosomes were also selected
according to their function and after literature mining of
genes related to drug resistance. The expression levels of
most of the selected genes were validated by RT-Real-time
PCR (Table 1). The correlation between microarray and
qPCR was calculated using the log-transformed values of
the fold change obtained for the selected genes, obtaining
an r-value of 0.95. To test if changes in the DNA content
were responsible for the expression levels of the selected
genes in the resistant cells, we determined the copy
number for all of them using Real-Time PCR. The results,
presented in table 1, showed amplification of all the genes
in chromosome 5 flanking dhfr, as well as of mtus1,
located in chromosome 8. E-cadherin was the only gene
clearly lost among the selected genes.
Effect on MTX sensitivity of siRNAs against genes flanking 
dhfr
To investigate if the genes that were both overexpressed
and co-amplified with dhfr contributed to MTX resistance,
their mRNA levels were brought down by means of siR-
NAs. Effective reduction (≈ 70%) of the respective mRNAs
was obtained upon transfection of 100 nM of each single
siRNA, both in sensitive and resistant cells. These treat-
ments, though, caused a small reduction in the viability of
both cell lines, and addition of MTX to the siRNAs did not
sensitize the cells toward the chemotherapeutic agent
(data not shown). On the contrary, a siRNA against dhfr
mRNA (siDHFR) caused a reduction in cell viability of
30% in HT29 sensitive cells, which was increased up to
90% with the addition of MTX (Figure 3B). mRNA levels
after siDHFR treatment were reduced by 70% in this cell
line (Figure 3A).
Table 1: mRNA levels and copy number determination of differentially expressed genes in HT29 MTX-resistant cells.
GenBank Gene Name Chromosome Copy Number 
(Q-PCR)
Expression Gene Function
Microarrays Validation (RT-PCR)
NM_002961 S100A4 1 0.85 ± 0.1 3.7 (p = 5.5e-6) 5.68 ± 0.4 Angiogenesis
BU078629 ZFYVE16 5 16.81 ± 2.1 6.1 (p = 7.7e-6) 6.7 ± < 0.1 Zinc ion binding
AI144299 DHFR 5 16.09 ± 1.4 7.1 (p = 1.2e-7) 11.05 ± 0.5 Nucleotide metabolism
NM_002439 MSH3 5 4.97 ± 0.5 3.9 (p = 5.5e-6) 4.23 ± 0.4 Missmatch repair
AI912976 RASGRF2 5 17.76 ± 0.4 4.6(p = 8.9e-5) 6.10 ± 0.5 MAPK signaling
AF912976 SSBP2 5 10.27 ± 0.7 2.4 (p = 3.4e-3) 2.96 ± 0.2 ss DNA binding
NM_022406 XRCC4 5 17.31 ± 1.1 7.1 (p = 4.7e-6) 8.90 ± 2.3 ds break repair
U43328 HAPLN1 5 11.55 ± < 0.1 147 (p = 2.9e-10) 1111.9 ± 80.7 Cell adhesion
AA053711 EDIL3 5 14.3 ± 0.7 157 (p = 9.1e-8) N/D Cell adhesion
U17496 PSMB8 6 0.91 ± < 0.1 0.1 (p = 0.01) N/D Proteasome subunit
NM_004666 VNN1 6 0.84 ± < 0.1 0.04 (p = 0.01) N/D Nitrogen metabolism
AU147399 CAV1 7 1.14 ± < 0.1 10.9 (p = 1.5e-4) 15.00 ± 0.8 Integ. plasma membr.
BE552421 MTUS1 8 3.52 ± 0.1 3.4 (p = 1.8e-6) N/D Mitoc. tumor suppressor
U05598 AKR1C1 10 0.94 ± < 0.1 4,6 (p = 3.9e-6) 6.72 ± 0.7 Xenobiotics metabolism
NM_001975 ENO2 12 0.92 ± < 0.1 6.0 (p = 4.6e-6) 3.90 ± 0.1 Glycolisis
AK000345 DHRS2 14 0.97 ± < 0.1 0.12 (p = 0.01) N/D Oxidoreductase
L08599 CDH1 16 0.33 ± < 0.1 0.19 (p = 0.01) 0.15 ± < 0.1 Cell adhesion
AI471375 PRKCA 17 1.05 ± < 0.1 4.2 (p = 1.7e-5) 2.55 ± 0.2 Regulation cell cycle
BQ003811 SLC19A1 21 0.84 ± < 0.1 0.1 (p = 0.01) N/D Cell adhesion
NM_001569 IRAK1 X 1.25 ± < 0.1 0.26 (p = 7.3e-3) N/D IL1 receptor Kinase
NM_004135 IDH3G X 0.85 ± < 0.1 0.28 (p = 7.3e-8) N/D TCA cycle
NM_001183 ATP6AP1 X 0.68 ± < 0.1 0.3 (p = 0.01) N/D ATP biosynthesis
Twenty-two genes belonging to the 3-fold differentially expressed list were selected according to their possible relation with drug resistance and/or 
chromosomal localization. It is shown the GenBank accession number of all genes next to their common name, and their chromosome number. 
Real-Time PCR was used to determine their copy number, and the expression levels for all them are presented both as the values found in the 
microarrays (in fold changes relative to the control; t-test p-values included) and as validated mRNA levels (using RT-Real-Time PCR). All 
experimental results are expressed as fold changes referred to the sensitive cells and values are the mean of triplicate experiments ± SE. The last 
column indicates the functional categories of the genes. N/D, nondetermined value.BMC Medical Genomics 2008, 1:35 http://www.biomedcentral.com/1755-8794/1/35
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Chromosomal view of the differentially expressed genes in HT29 MTX-resistant cells Figure 1
Chromosomal view of the differentially expressed genes in HT29 MTX-resistant cells. The expression values of 
genes included in the 3-fold differentially expressed list were viewed in their respective chromosomal location. The names for 
all the genes studied are depicted on top of their chromosome position. Red is used to color the overexpressed genes and 
blue is used to highlight the underexpressed genes.
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Localization of dhfr and other genes in chromosome 5 that are overexpressed in HT29 MTX-resistant cells Figure 2
Localization of dhfr and other genes in chromosome 5 that are overexpressed in HT29 MTX-resistant cells. It is 
presented a magnification of the region in chromosome 5 where dhfr is located (5q14). The left part is an ideogram of chromo-
some 5; the right part shows the relative position of all genes studied that are located in this chromosome and that were ampli-
fied. The arrows indicate their transcription orientation and the values in parentheses under the names correspond to their 
respective copy-number validated by Real-time PCR.
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Determination of mRNA levels and cytotoxicity upon siRNA treatment of HT29 sensitive cells Figure 3
Determination of mRNA levels and cytotoxicity upon siRNA treatment of HT29 sensitive cells. (A) The mRNA 
levels of CAV1, ENO2, PKCα and DHFR were determined by RT-Real-time PCR 48 h after treatment of HT29 cells with the 
indicated concentrations of siCAV1, siENO2, siPKCα, siDHFR and a non-related siRNA. Symbols used for each mRNA are 
presented as an insert within the figure. (B) Cells were treated with 100 nM of each siRNA as previously described and 5 × 10-
8 M MTX was added after 48 h. Cell viability was determined after 5 days from the beginning of the treatment. All results are 
expressed as percentages referred to untreated cells. Values are the mean of three independent experiments ± SE. A non-
related (NR) siRNA was used as negative control.
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Effect on MTX sensitivity of siRNAs against CAV1, ENO2, 
PKCα and DHFR
As the knocking down of genes co-amplified with dhfr
showed only a slight contribution to MTX sensitivity, we
focused in three genes that were clearly overexpressed in
the resistant cells and located in different chromosomes,
namely caveolin 1(CAV1), enolase 2 (ENO2) and PKCα.
We quantified the mRNA levels of these three genes after
treatment with different concentrations of the corre-
sponding siRNA using RT-Real-time PCR. The three siR-
NAs were effective in reducing the mRNA levels of their
targets, both in sensitive (Figure 3A) and in MTX-resistant
(Figure 4) HT29 cells. One hundred nanomolar was the
most effective concentration for all of them, and was used
in subsequent experiments. The mRNA levels upon treat-
ment with the siRNA against DHFR are also presented in
these series (Figure 3A &4). The mRNA levels of the four
genes after treatment with their respective siRNAs in the
resistant cells were reduced down almost to the expression
levels found for these genes in HT29 sensitive cells (com-
pare Y-axes between Figure 3A &4). A non-related siRNA
was used as negative control, and did not produce any sig-
nificant reduction on the mRNA levels of any of the four
genes, either in sensitive or in resistant HT29 cells.
Viability of HT29 sensitive cells (Figure 3B) was moder-
ately reduced upon treatment with 100 nM siENO2 or
siDHFR and treatment with siCAV1 caused a marked
reduction of cell viability on its own. No effect on cell via-
bility was observed upon treatment with siPKCα. In all
cases, treatment with 100 nM of each single siRNA
increased the sensitivity of HT29 cells toward MTX with
respect to the control: 80% when using siCAV1; 70% with
siENO2; 40% with siPKCα and 90% when siDHFR was
used. However, when the same treatments were per-
formed in MTX-resistant cells (data not shown), cell via-
bility was reduced only by 15% when using either siCAV1,
siENO2 or siPKCα, and by 25% when siDHFR was used.
None of these effects were improved by the combination
of siRNAs with MTX. Transfection with 100 nM of a non-
related siRNA did not cause any significant reduction on
cell viability, either in sensitive or in resistant HT29 cells.
Effect of the combination of siRNAs against CAV1, ENO2, 
PKCα and DHFR on MTX sensitivity
As we had observed a chemosensitization toward MTX in
sensitive cells when using individual siRNAs, we per-
formed experiments including the siRNAs against CAV1,
ENO2 and PKCα (triple combination) or in combination
with siDHFR (quadruple combination) to test if these
combinations also increased the sensitivity toward MTX.
Treatments combining the three siRNAs (siCAV1, siENO2
and siPKCα) at 100 nM each reduced cell viability by 30%
and effectively increased MTX sensitivity by 60% with
respect to the control in HT29 sensitive cells (Figure 5A).
Addition of 100 nM siDHFR to the previous combination
caused a reduction on cell viability of the same degree as
the triple combination but increased MTX sensitivity to
about 75%. In the case of MTX-resistant HT29 cells, treat-
ments were performed with the same combinations (Fig-
ure 5B). The triple combination reduced cell viability by
15% on its own. However, MTX sensitivity was not
improved. The quadruple combination did not affect cell
viability on its own but caused a reduction of 20% on cell
viability when combined with MTX. It was confirmed that
the mRNA levels of the four genes were decreased after the
siRNA combination treatments in both cell lines (Table
2). Treatments with a non-related siRNA at 400 nM were
performed in order to assess the citotoxicity of triple and
quadruple combinations and to verify the mRNA levels of
all four genes. No effect was observed in any case in either
sensitive or resistant cells.
Effect of overexpressing E-cadherin on its mRNA levels, 
cell viability and MTX sensitivity
Since E-cadherin was lost and underexpressed in the
resistant cells, it was transiently expressed in HT29 sensi-
tive and resistant cells by means of an expression vector
(pBATEM2-CDH). Cells were harvested after 48 hours of
treatment. RT-Real-Time PCR was used to quantify E-cad-
herin mRNA levels in both cell lines (Figure 6A &6B).
Transfection of more than 1 μg of the expression vector
caused a marked reduction on cell viability in both cell
lines. Therefore, 1 μg of plasmid was used in all subse-
quent experiments. Overexpression of E-cadherin was per-
formed in HT29 sensitive cells in the absence or in the
presence of 5 × 10-8 M MTX. This treatment increased by
50% the effect of methotrexate (Figure 6C), thus provid-
ing evidence that loss of E-cadherin can confer increased
resistance of HT29 cells toward MTX. The same approach
was used with HT29 resistant cells, in combination or not
with 10-5 M MTX. Overexpression of E-cadherin reduced
by 10% cell viability of the resistant cells and only a small
improvement was observed when combining E-cadherin
overexpression with MTX treatment (Figure 6D).
Effect of co-transfection of siCAV1 and pBATEM2-CDH on 
MTX sensitivity
E-cadherin has been shown to be an important permissive
element in defining the functions of CAV1 [16]. Thus, we
performed co-transfection experiments to reduce the
mRNA levels of CAV1 and to overexpress E-cadherin
simultaneously. mRNA levels after co-transfection were
determined in both cell lines (Table 3). As observed in fig-
ure 7A, altering the mRNA levels for the two genes
reduced the viability of HT29 sensitive cells by almost
40%. Moreover, addition of MTX to the previous combi-
nation further reduced cell viability by 90%. Importantly,
when performing these co-transfection experiments in
HT29 resistant cells, cell viability was reduced by 80%,BMC Medical Genomics 2008, 1:35 http://www.biomedcentral.com/1755-8794/1/35
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mRNA levels of CAV1, ENO2, PKCα and DHFR upon siRNA treatment of MTX-resistant cells Figure 4
mRNA levels of CAV1, ENO2, PKCα and DHFR upon siRNA treatment of MTX-resistant cells. Treatments with 
increasing amounts of each siRNA were performed in MTX-resistant HT29 cells. Forty-eight hours later, mRNA levels for 
each gene were determined and expressed as percentages of the untreated control (A, CAV1; B, ENO2; C, PKCα and D, 
DHFR). A non-related (NR) siRNA was used as negative control. Results are depicted taking into account the relative gene 
expression in the resistant cells (% of the sensitive cells). Values are the mean of three independent experiments ± SE.
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although in this instance MTX did not improve the effect
(Figure 7B).
Discussion
In the present study, genes differentially expressed in
HT29 colon cancer cells resistant to MTX were identified
and their relative contribution to this phenotype evalu-
ated. We observed a cluster of genes flanking the dhfr locus
in chromosome 5 that were overexpressed in MTX-resist-
ant HT29 cells. Two of the genes included in this cluster,
MSH3 and XRCC4, are known to be involved in DNA
repair [17-19]; other two, RASGRF2 and SSBP2, have been
related to signaling pathways [20-22]; and EDIL3 has
been suggested to prevent apoptosis and to promote cell
proliferation [23,24]. Despite the confirmation of the co-
amplification of all these genes with dhfr in the resistant
cells, we did not observe a clear sensitization toward MTX
when reducing their respective mRNA levels by means of
iRNA technology. Our observations indicate that the
increase in copy-number and the resulting upregulation
of the studied genes in 5q14 may be a consequence of dhfr
amplification more than an adaptation of the cells to MTX
resistance. Indeed, many mammalian species (mouse, rat,
bull, cock, dog and chimpanzee) show this set of genes in
the same order around dhfr as in human chromosome 5
(using the MapViewer at NCBI), indicating a conserved
pattern of gene organization. In keeping with this, its
overexpression in the resistant cells could have been use-
ful to improve some cellular processes that might facilitate
survival. However, as shown in this work, the increase in
copy number of this set of genes does not favor MTX
resistance. Thus, we decided to search for other differen-
tially expressed genes (CAV1, E-cadherin, ENO2 and
PKCα) that had been previously related with resistance or
with colon cancer and to evaluate their relative contribu-
tion in our cell system.
Effects of combining siRNAs against CAV1, ENO2, PKCα and DHFR on MTX sensitivity Figure 5
Effects of combining siRNAs against CAV1, ENO2, PKCα and DHFR on MTX sensitivity. Treatments with combi-
nations of siRNAs at100 nM each were performed both in sensitive (A) and in resistant cells (B). MTX was added after 48 h 
and cell viability was determined by the MTT assay after 5 days from the beginning of the treatment. The triple combination 
includes the siRNAs against CAV1, ENO2 and PKCα; the quadruple combination includes the three previous siRNAs plus siD-
HFR. Results are presented as percentages referred to the untreated cells. Values are the mean of three independent experi-
ments ± SE.
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Enolase 2 (ENO2) is induced by hypoxia, an intrinsic con-
dition of tumors. Moreover, ENO2 is a glycolysis-related
gene that has been described to play an important role in
tumorogenesis of colorectal cancers [25]. Indeed, ENO2 is
upregulated in a variety of cancers [26-28] and alpha-eno-
lase is significantly upregulated in a metastasic colon can-
cer cell line, suggesting a possible association with the
metastasic process in vitro and in vivo [29]. Indeed, we
observed a notable contribution of ENO2 to MTX resist-
ance when treating the sensitive cells with siENO2.
Both the α-isozyme of PKC and caveolin 1 has been
described to be associated with multidrug resistance
[30,31], and thus represent good targets to be analyzed.
PKCα phosphorylates different proteins, which triggers a
wide variety of cellular responses including proliferation,
differentiation, membrane transport, gene expression and
tumor promotion [32,33]. Chemical inhibitors of PKC
activity have been proposed as resistance modulators in
MTX chemotherapy [34]. Furthermore, decreasing PKCα
mRNA levels attenuates the MDR phenotype in tumor
cells [35] and increases the sensitivity to anticancer drugs,
both in vitro [36-38] and in vivo [39]. These observations
are in accordance with our result showing that the
decrease of PKCα mRNA levels by means of iRNA technol-
ogy causes a sensitization of the cells toward MTX. Caveo-
lin 1 (CAV1), the principal component of caveolae, has
been associated with progression of colon and breast car-
cinomas [40,41] and with enhanced invasiveness in lung
adenocarcinoma cells [42]. Although suggested as tumor
suppressor gene, and downregulated in some oncogene-
transformed and tumor-derived cells [31], overexpression
of CAV1 has been found in prostate and esophageal can-
cer [43-45]. Moreover, re-expression of CAV1 at latter
stages of tumor development has been described in
human and mouse prostate adenocarcinomas [41], a sce-
nario that could resemble chemotherapy resistance.
Indeed, Bender et al. [46] found significantly higher levels
of CAV1 in MTX resistant HT29 clones. We have con-
firmed the implication of CAV1 in MTX resistance in our
HT29 cell line.
Nevertheless, as Benimetskaya and collaborators observed
with PKCα [47], downregulation of a gene alone may be
insufficient to completely chemosensitize the cells. There-
fore, we considered a combination therapy in order to
improve MTX sensitivity. As shown in figure 5, the combi-
nation of siRNAs against CAV1, ENO2 and PKCα sensi-
tizes the cells toward MTX, and the effect is improved by
the additional downregulation of DHFR. The effects of the
triple or the quadruple combinations, however, are not
the sum of the effects caused by each single siRNA. This
probably reflects the difficulty of transfecting more than
one siRNA at 100 nM each. Indeed, the mRNA levels for
the four genes after the combination treatment were not
as reduced as with the single treatments. In the case of all
treatments performed in the resistant cells, probably the
overexpression by amplification of the dhfr locus was pow-
erful enough to mask the effects of the siRNAs used.
Not only the overexpression of some genes may cause the
resistance phenotype. One of the most underexpressed
genes that we confirmed to be clearly lost in our HT29
MTX-resistant cells is E-cadherin. In fact, loss of E-cadherin,
frequently observed in epithelial tumors, has been associ-
ated with tumor progression [48,49] and is considered a
crucial event that favors metastasis and invasiveness
[50,51]. In addition, the mRNA levels of E-cadherin in
Table 2: mRNA levels upon treatment with combination of siRNAs against CAV1, ENO2, PKCα and DHFR.
A
Treatment CAV1 ENO2 PKCα DHFR
siCAV1 + siENO2 + siPKCα 50.1 ± 4.3 50.5 ± 4.4 66.2 ± 2.6 82.9 ± 2.3
siCAV1 + siENO2 + siPKCα + siDHFR 37.7 ± 3.7 59.1 ± 0.8 47.6 ± 4.7 47.3 ± 1.2
400 nM NR-siRNA 96.8 ± 10.4 98.4 ± 0.5 96.3 ± 0.3 100.6 ± 13.4
B
Treatment CAV1 ENO2 PKCα DHFR
siCAV1 + siENO2 + siPKCα 62.7 ± 0.2 44.20 ± 0.9 73.2 ± 4.9 97.7 ± 8.8
siCAV1 + siENO2 + siPKCα + siDHFR 45.4 ± 0.8 36.34 ± 4.2 40.6 ± 2.5 33.4 ± 3.8
400 nM NR-siRNA 99.1 ± 9.2 100.57 ± 15.9 103.2 ± 1.1 95.5 ± 10.2
Treatments combining the siRNAs against CAV1, ENO2 and PKCα at 100 nM each were performed both in sensitive (A) and in resistant (B) HT29 
cells. The mRNA levels for all three genes were determined at 48 hours of treatment. DHFR mRNA levels were also determined. Treatments 
combining 100 nM of the previous three siRNAs plus a siRNA against DHFR were also performed in both cell lines and mRNA levels for the four 
genes quantified by RT-Real-Time PCR. A non-related (NR) siRNA was used as negative control. Results are expressed as percentages of mRNA 
referred to untreated cells (mean ± SE) of triplicate experiments.BMC Medical Genomics 2008, 1:35 http://www.biomedcentral.com/1755-8794/1/35
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Determination of mRNA levels and cytotoxicity upon overexpression of E-cadherin Figure 6
Determination of mRNA levels and cytotoxicity upon overexpression of E-cadherin. Cells were treated with 
increasing amounts of an expression plasmid encoding for E-cadherin (pBATEM2-CDH). Forty-eight hours after the treatment, 
mRNA levels were determined in HT29 sensitive (A) and MTX-resistant cells (B). Three independent experiments were per-
formed and results are expressed as percentages referred to untreated cells. Values are the mean ± SE. Simultaneous experi-
ments of cells transfected with pBATEM2-CDH were treated with MTX 48 h after transfection, and viability of both sensitive 
(C) and MTX-resistant cells (D) was assessed after 5 days from the beginning of the treatment by the MTT assay. The mean 
value ± SE of three independent experiments is depicted. An empty plasmid was used as negative control both for mRNA lev-
els and cytotoxicity determination.
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adenocarcinoma are 2-fold lower than in normal colon
cells [52]. Thus, there is a functional correlation between
E-cadherin levels and malignancy. It has been described
an event of loss of heterozygosity at the 16.1q chromo-
some band in most human prostate cancers, where E-cad-
herin is located [53], which is associated with tumor grade,
advanced clinical stage and poor survival [54]. Our exper-
iments show a decrease of 3-fold in E-cadherin levels in
resistant cells and also that a mild overexpression of E-
cadherin causes a higher sensitivity toward MTX. One has
to be cautious, however, about the expression levels of E-
cadherin since an increase of more than 3-fold in any of
both cell lines caused a reduction in cell viability. This is
in accordance with the experiments of Derksen et al. [55]
that suggested that loss of E-cadherin could play a causal
role in the acquisition of anoikis resistance, as parental
mammary cells lacking E-cadherin survived while re-
expression of the gene caused apoptosis [55]. Previous
works show that loss of E-cadherin in either skin or mam-
mary epithelium does not induce tumor formation [55].
Thus, an overall view of the events occurring in our HT29
cells resistant to methotrexate is needed.
It has been shown that activated PKCα translocates from
the nucleus to the membrane [56], where it associates
with caveolae [57,58], and regulates the function and for-
mation of such biological structures. PKCα has been
described to directly interact with CAV1. The union is per-
formed between the caveolin 1 scaffolding domain pep-
tide and PKCα caveolin 1 binding motif [59]. Further,
activation of PKCα by phorbol esters dislocates the
enzyme from caveolae. All these observations indicate
that PKCα interacts functionally with this membrane
structures. Moreover, PKCα has been proposed to be
involved in the rearrangement of the cytoskeleton. Masur
et al. showed that a high level of PKCα expression plus a
low E-cadherin level predicts an elevated migratory activ-
ity of colon carcinoma cells, which could be derived more
easily to metastasis [56]. Lahn et al. speculate that PKCα
overexpression may represent an important cellular event
leading to enhanced tumor progression, as they con-
cluded that MCF-7 breast cancer cells transfected with
PKCα had reduced expression of E-cadherin and β-cat-
enin, resulting in a loss of cell-cell adhesion and thus in a
more aggressive tumor phenotype [38].
Specific protein-protein interactions between CAV1 and
other proteins have been proposed to regulate cell signal-
ing [57,60]. Indeed, CAV1 is known to control cell prolif-
eration and viability by inhibiting expression of survivin,
a member of the IAP (inhibitor of apoptosis) family via a
transcriptional mechanism involving the β-catenin-Tcf/
Lef-1 pathway [16]. One of the possible locations of β-cat-
enin is within a complex with E-cadherin in the adherence
junctions, specialized cell-cell adhesion sites that link the
cadherin molecules to the actin microfilaments [61]. E-
cadherin promotes co-localization and co-imunoprecipi-
tation of CAV1 with β-catenin, as well as inhibition of β-
catenin-Tcf/Lef-1 dependent transcription of a wide vari-
ety of genes regulated by this pathway, among which sur-
vivin is found. However, the ability of CAV1 to regulate
survivin expression and cell proliferation is severely
impaired in metastasic cancer cells lacking E-cadherin
[16]. If E-cadherin is lost, β-catenin is not retained in the
plasma membrane and can be then translocated into the
nucleus [62], thus activating Tcf/Lef-1 transcription fac-
tors-mediated expression of genes implicated in cell pro-
liferation and tumor progression [50]. E-cadherin has
been shown to be an important permissive element in
defining the functions of CAV1, since several characteris-
tics potentially relevant to CAV1 function as a tumor sup-
pressor are compromised in E-cadherin-deficient HT29
cells [16]. A diagram showing all these relations is pre-
sented in Figure 8.
Our results show that HT29 cells can be well sensitized
toward MTX by simultaneous treatment with siCAV1 and
pBATEM2-CDH. Importantly, we can revert the resistant
scenario by reducing the levels of caveolin 1 and by over-
expressing E-cadherin simultaneously in the resistant
cells, demonstrating the roles that play both genes in MTX
resistance.
Conclusion
We demonstrate that, aside from dhfr, the contribution of
the 5q14 co-amplified genes to MTX resistance is small in
HT29 colon cancer cells. On the other hand, we have
identified genes deregulated in MTX resistant cells and
have demonstrated a role for caveolin 1, E-cadherin, eno-
lase 2 and PKCα in MTX resistance. Very importantly, the
concomitant knocking down of CAV1 with overexpres-
Table 3: mRNA levels upon treatment with siCAV1 and pBATEM2-CDH.
Treatment Cell line CAV1 E-cadherin
siCAV1 + pBATEM2-CDH HT29 sensitive 21.8 ± 1.9 252.3 ± 3.5
siCAV1 + pBATEM2-CDH HT29 resistant 25.6 ± 0.2 199.7 ± 16.9
Transfection experiments combining the siRNA against caveolin 1 (siCAV1) and the expression plasmid for E-cadherin (pBATEM2-CDH) were 
performed both in HT29 sensitive and MTX-resistant cells. Forty-eight hours later, mRNA levels for the two genes were determined in both cell 
lines by RT-Real-Time RCR. Results are expressed as percentages of mRNA referred to untreated cells (mean ± SE) of at least 3 independent 
experiments.BMC Medical Genomics 2008, 1:35 http://www.biomedcentral.com/1755-8794/1/35
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Effect of combining the siRNA against CAV1 and the expression plasmid for E-cadherin Figure 7
Effect of combining the siRNA against CAV1 and the expression plasmid for E-cadherin. One hundred nanomolar 
siRNA against CAV1 and 1 μg of the expression plasmid for E-cadherin were transfected in both sensitive (A) and resistant (B) 
HT29 cells. MTX was added 48 hours after transfection and the MTT assay was used to determine cell viability. Results are 
expressed as percentages referred to untreated cells. Values are the mean of three independent experiments ± SE.
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sion of E-cadherin in HT29 resistant cells markedly
reduced cell viability.
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Scheme for HT29 sensitive and MTX-resistant cells Figure 8
Scheme for HT29 sensitive and MTX-resistant cells. A diagram is presented showing the compartment localization of 
CAV1, E-cadherin (E-CDH) and β-catenin (β-CAT) in HT29 sensitive cells (with E-cadherin) and MTX-resistant cells (without 
E-cadherin, gene loss) and the effects caused by this differential situation. In the sensitive cells, β-catenin is located in the adher-
ence junctions within a complex with E-cadherin. CAV1 co-localizes with β-catenin in these complexes, interfering in β-CAT 
signaling. If E-cadherin is lost, as in the resistant cells, β-catenin is not retained in the plasma membrane and then can be translo-
cated into the nucleus, thus activating Tcf/Lef-1 transcription factors-mediated expression of genes implicated in cell prolifera-
tion and tumor progression.
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